Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of 9MW2921 in advanced solid tumors
CTR20232341Phase 2Active
- Sponsor
- Maiwei Biotech
- Start
- Aug 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 9MW2921 in Nonhematologic neoplasms, sponsored by Maiwei Biotech. Primary endpoints: Dose-limiting toxicities, Adverse events and 1 more. Started Aug 2023; status: active.
02
Drugs
9MW2921
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20232341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232341.